Histopathological lesions in encephalon and heart of mice infected with Toxoplasma gondii increase after Lycopodium clavatum 200dH treatment.

In many cases, symptoms of toxoplasmosis are mistaken for the ones of other infectious diseases. Clinical signs are rare in immunocompetent people. However, when they arise, in the acute phase of infection, several organs are affected due to the rapid spread of tachyzoites through the bloodstream. In the present study, the reduction of tachyzoites in peripheral blood of mice of G72 (infected 72h after treatment) and G48 (infected 48h after treatment and treated three more times), when compared with IC (infected and non-treated), suggests protective effect exerted by Lycopodium clavatum. If on the one hand L. clavatum brought benefits, reducing parasitemia, on the other hand, the parasitism became exacerbated. Histopathological analysis demonstrated focal, multifocal and diffuse inflammatory infiltrates, ranging from absent, discreet, moderate to intense, in heart and encephalon of mice of NIC (non-infected and non-treated), IC, G48 and G72 groups, respectively. In the perivascular region and meninges, the injuries were enlarged. The presence of tachyzoites was demonstrated through immunohistochemical (IHC) assay in myocardium. Toxoplasma gondii induced increase of collagen fibers in myocardium of mice of G72 and G48 groups, compared with IC (p<0.05) and NIC (p<0.001). The presence of inflammatory infiltrates, as well as the progressive fibrosis, caused myocardial remodeling in animals treated with L. clavatum. Counterstaining with H&E suggests TGF-ß expression by mononuclear cells in the inflammatory infiltrate. Based on our results, we can conclude that the adopted regimen and potency exerted a protective effect, reducing parasitemia. However, it intensified the histopathological lesions in encephalon and heart of mice infected with T. gondii.

Isolation of dengue virus serotype 4 genotype II from a patient with high viral load and a mixed Th1/Th17 inflammatory cytokine profile in South Brazil.

BACKGROUND: We report the isolation and characterization of dengue virus (DENV) serotype 4 from a resident of Santa Fé, state of Paraná, South Brazil, in March 2013. This patient presented with hemorrhagic manifestations, high viral load and, interestingly, a mixed Th1/Th17 cytokine profile. CASE PRESENTATION: The patient presented with classical dengue symptoms, such as fever, rash, myalgia, arthralgia, and hemorrhagic manifestations including petechiae, gum bleeding and a positive tourniquet test result. A serum sample obtained 1 day after the initial appearance of clinical symptoms was positive for NS1 viral antigen, but this sample was negative for both IgM and IgG against DENV. Dengue virus infection was confirmed by isolation of the virus from C6/36 cells, and dengue virus serotyping was performed via one-step RT-PCR. The infection was confirmed to be caused by a serotype 4 dengue virus. Additionally, based on multiple alignment and phylogeny analyses of its complete genome sequence, the viral strain was classified as genotype II (termed LRV13/422). Moreover, a mixed Th1/Th17 cytokine profile was detected in the patient's serum, and this result demonstrated significant inflammation. Biological characterization of the virus via in vitro assays comparing LRV13/422 with a laboratory-adapted reference strain of dengue virus serotype 4 (TVP/360) showed that LRV13/422 infects both vertebrate and invertebrate cell lines more efficiently than TVP/360. However, LRV13/422 was unable to inhibit type I interferon responses, as suggested by the results obtained for other dengue virus strains. Furthermore, LRV13/422 is the first completely sequenced serotype 4 dengue virus isolated in South Brazil. CONCLUSION: The high viral load and mixed Th1/Th17 cytokine profile observed in the patient's serum could have implications for the development of the hemorrhagic signs observed, and these potential relationships can now be further studied using suitable animal models and/or in vitro systems.

Leishmanicidal activity of brazilian propolis hydroalcoholic extract in Leishmania amazonensis / Atividade leishmanicida de extrato hidroalcoólico de própolisbrasileira em Leishmania amazonensis

As leishmanioses são consideradas doenças negligenciadas devido às altas incidências, ampla distribuição geográfica e dificuldade no tratamento sendo incluídas na relação de doenças prioritárias pela Organização Mundial da Saúde. Os tratamentos disponíveis para estas doenças apresentam elevada toxicidade,justificando a busca por fármacos alternativos. Estudos prévios com própolis, resina produzida por abelhas,demonstraram sua atividade antiparasitária e imunomoduladora em diversos modelos experimentais. O objetivo deste trabalho foi avaliar o efeito in vitro do extrato hidroalcoólico de própolis brasileira, coletadona cidade de Botucatu no estado de São Paulo, sobre formas promastigotas de Leishmania amazonensis, bem como analisar seu efeito in vivo sobre a carga parasitária em baço de camundongos susceptíveis à infecção. Assim, formas promastigotas tratadas com extrato hidroalcoólico de própolis brasileira nas concentrações 5, 10, 25, 50 ou 100 µg/mL apresentaram efeito inibitório sobre a proliferação desses parasitos nos tempos de 24, 96 e 168 h. No entanto, as concentrações de 50 e 100 µg/mL mostraram-se mais eficazes quando comparadas ao controle e às demais concentrações em todos os tempos avaliados.Em relação à carga parasitária, após 30 dias de infecção com L. amazonensis, camundongos BALB/c foram tratados diariamente com a própolis (5mg/kg), via oral ou intraperitoneal, durante 60 dias. Posteriormente,o baço destes animais foi coletado para análise da carga parasitária. O tratamento por via oral reduziu 40%da carga parasitária. Desta forma, a amostra de própolis brasileira testada apresentou ação leishmanicida sobre L. amazonensis em cultura e em camundongos infectados com este protozoário.

Leishmaniosis are considered neglected diseases due to its high incidence, widespread and difficultyin treatment being included in the list of priority diseases by the World Health Organization. Available treatments for these diseases have high toxicity, which explains the search for more effective drugs. Previous studies with propolis - a resinous substance produced by bees - demonstrated immunomodulatory and anti-parasitic activity in several experimental models. The objective of this study was to evaluatethe effect in vitro of Brazilian propolis hydroalcoholic extract, collected in the city of Botucatu in SãoPaulo State, on promastigotes forms of Leishmania amazonensis as well as its effect on the parasiteload in the spleen of infected mice. Thus, promastigote forms treated with 5, 10, 25, 50 or 100 μg/mLof Brazilian propolis hydroalcoholic extract at 24, 96 and 168 hours showed inhibitory effect on the spread of these pararasite at all indicated times. However, the concentrations of 50 and 100 μg/mL were more effective, reducing the parasite spread when compared to the control and other concentrations at all times. Regarding parasitic load, after 30 days of infection with L. amazonensis, BALB/c mice were treated on a daily basis with propolis (5mg/kg) orally or intraperitoneally for 60 days. Further, the spleen was collected for parasite load analysis. Oral treatment reduced 40% of the parasitic load. Thus, the tested Brazilian propolis sample showed antileishmanial activity on L. amazonensis in culture andin parasite- infected mice.

Kaurenoic Acid Possesses Leishmanicidal Activity by Triggering a NLRP12/IL-1ß/cNOS/NO Pathway.

Leishmania amazonensis (L. amazonensis) infection can cause severe local and diffuse injuries in humans, a condition clinically known as American cutaneous leishmaniasis (ACL). Currently, the therapeutic approach for ACL is based on Glucantime, which shows high toxicity and poor effectiveness. Therefore, ACL remains a neglected disease with limited options for treatment. Herein, the in vitro antiprotozoal effect and mechanisms of the diterpene kaurenoic acid [ent-kaur-16-en-19-oic acid] (KA) against L. amazonensis were investigated. KA exhibited a direct antileishmanial effect on L. amazonensis promastigotes. Importantly, KA also reduced the intracellular number of amastigote forms and percentage of infected peritoneal macrophages of BALB/c mice. Mechanistically, KA treatment reestablished the production of nitric oxide (NO) in a constitutive NO synthase- (cNOS-) dependent manner, subverting the NO-depleting escape mechanism of L. amazonensis. Furthermore, KA induced increased production of IL-1ß and expression of the inflammasome-activating component NLRP12. These findings demonstrate the leishmanicidal capability of KA against L. amazonensis in macrophage culture by triggering a NLRP12/IL-1ß/cNOS/NO mechanism.

Nitric oxide and Brazilian propolis combined accelerates tissue repair by modulating cell migration, cytokine production and collagen deposition in experimental leishmaniasis.

The fact that drugs currently used in the treatment of Leishmania are highly toxic and associated with acquired resistance has promoted the search for new therapies for treating American tegumentary leishmaniasis (ATL). In this study, BALB/c mice were injected in the hind paw with Leishmania (Leishmania) amazonensis and subsequently treated with a combination of nitric oxide (NO) donor (cis-[Ru(bpy) 2imN(NO)](PF6)3) (Ru-NO), given by intraperitoneal injection, and oral Brazilian propolis for 30 days. Ru-NO reached the center of the lesion and increased the NO level in the injured hind paw without lesion exacerbation. Histological and immunological parameters of chronic inflammation showed that this combined treatment increased the efficacy of macrophages, determined by the decrease in the number of parasitized cells, leading to reduced expression of proinflammatory and tissue damage markers. In addition, these drugs in combination fostered wound healing, enhanced the number of fibroblasts, pro-healing cytokines and induced collagen synthesis at the lesion site. Overall, our findings suggest that the combination of the NO donor Ru-NO and Brazilian propolis alleviates experimental ATL lesions, highlighting a new therapeutic option that can be considered for further in vivo investigations as a candidate for the treatment of cutaneous leishmaniasis.

Brazilian propolis antileishmanial and immunomodulatory effects.

The antileishmanial and immunomodulatory effects of propolis collected in Botucatu, São Paulo State, Brazil, were evaluated in Leishmania (Viannia) braziliensis experimental infection. The antileishmanial effect of propolis on promastigote forms was verified by reducing growth and by promoting morphologic alterations observed by scanning electron microscopy. In in vitro immunomodulatory assays, macrophages were pretreated with propolis and then infected with L. (V.) braziliensis. In vivo, supernatants from liver cells and peritoneal exudate of BALB/c mice pretreated with propolis and infected with Leishmania (10(7)/mL promastigotes) were collected, and TNF-α and IL-12 were measured by ELISA. Macrophages incubated with propolis showed a significant increase in interiorization and further killing of parasites. An increased TNF-α production was seen in mice pretreated with propolis, whereas IL-12 was downregulated during the infection. In conclusion, Brazilian propolis showed a direct action on the parasite and displayed immunomodulatory effects on murine macrophages, even though the parasite has been reported to affect the activation pathways of the cell. The observed effects could be associated with the presence of phenolic compounds (flavonoids, aromatic acids, and benzopyranes), di- and triterpenes, and essential oils found in our propolis sample.